Trimodality Versus Bimodality Therapy in Patients With Locally Advanced Esophageal Carcinoma: Commentary on the American Society of Clinical Oncology Practice Guidelines

Lucas K Vitzthum; Caressa Hui; Erqi L Pollom; Daniel T Chang

doi:10.1016/j.prro.2021.05.004

Trimodality Versus Bimodality Therapy in Patients With Locally Advanced Esophageal Carcinoma: Commentary on the American Society of Clinical Oncology Practice Guidelines

Pract Radiat Oncol. 2021 Nov-Dec;11(6):429-433. doi: 10.1016/j.prro.2021.05.004. Epub 2021 Aug 2.

Authors

Lucas K Vitzthum¹, Caressa Hui¹, Erqi L Pollom¹, Daniel T Chang²

Affiliations

¹ Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California.
² Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California. Electronic address: [email protected].

PMID: 34353757
DOI: 10.1016/j.prro.2021.05.004

Abstract

In the recent guideline statement from the American Society of Clinical Oncology, experts reviewed relevant literature and provided treatment recommendations for multimodality treatment approaches. The guidelines recommend either preoperative concurrent neoadjuvant chemoradiotherapy (CRT) or perioperative chemotherapy for locally advanced adenocarcinoma and either preoperative CRT followed by esophagectomy or definitive CRT for squamous cell carcinoma. Whether radiation can be omitted in patients with adenocarcinoma or whether surgery can be omitted in patients with squamous cell carcinoma is a subject of ongoing debate and clinical trials.

MeSH terms

Carcinoma, Squamous Cell* / pathology
Chemoradiotherapy
Esophageal Neoplasms* / pathology
Esophageal Neoplasms* / therapy
Esophagectomy
Humans
Medical Oncology
Neoadjuvant Therapy
Neoplasm Staging
United States